Literature DB >> 2647811

Pathophysiology and current therapy of congestive heart failure.

W W Parmley1.   

Abstract

Congestive heart failure is a common clinical syndrome, with a relatively poor prognosis in its advanced stages. During the development of heart failure, there is a decline in myocardial contractility and activation of neurohormonal systems. An overshoot of some of these compensatory mechanisms sets the stage for therapeutic interventions. Any of the three therapeutic classes of drugs (inotropic drugs, diuretics or vasodilators) can be used as first-line therapy. Other classes can be added to produce additive effects on ventricular function. Because vasodilators have been shown to prolong life, they should be used routinely in patients with heart failure. Arrhythmias and sudden death are relatively common in heart failure, although the value of antiarrhythmic therapy is less certain. Although current therapy is very helpful in patients with heart failure, it is clear that preventive approaches will be more effective in decreasing morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2647811     DOI: 10.1016/0735-1097(89)90215-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  21 in total

1.  After-effects of exercise on haemodynamics and muscle sympathetic nerve activity in young patients with dilated cardiomyopathy.

Authors:  K Hara; J S Floras
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 2.  Early intervention in heart failure.

Authors:  M A Creager
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 3.  Recent advances in the treatment of congestive heart failure.

Authors:  S C Chen
Journal:  Indian J Pediatr       Date:  1998 Jan-Feb       Impact factor: 1.967

4.  Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model.

Authors:  B A van Hout; G Wielink; G J Bonsel; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 5.  Modulation of angiotensin II signaling following exercise training in heart failure.

Authors:  Irving H Zucker; Harold D Schultz; Kaushik P Patel; Hanjun Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-13       Impact factor: 4.733

Review 6.  Ventricular arrhythmias in congestive heart failure: clinical significance and management.

Authors:  G R Khoshnevis; A Massumi
Journal:  Tex Heart Inst J       Date:  1999

Review 7.  The cardiorenal syndrome: lessons from the ADHERE database and treatment options.

Authors:  J Thomas Heywood
Journal:  Heart Fail Rev       Date:  2004-07       Impact factor: 4.214

Review 8.  Acute and chronic adaptation to hemodynamic overload and ischemia in the aged heart.

Authors:  Shogen Isoyama; Yuko Nitta-Komatsubara
Journal:  Heart Fail Rev       Date:  2002-01       Impact factor: 4.214

Review 9.  Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.

Authors:  A Fitton; R N Brogden
Journal:  Drugs Aging       Date:  1994-05       Impact factor: 3.923

10.  The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy.

Authors:  A B Lewis; M Chabot
Journal:  Pediatr Cardiol       Date:  1993-01       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.